Table 1 Summary of model inputs
Model input | Value | Notes/sources |
|---|---|---|
Utility inputs for disease states | ||
 Stable disease: ceritinib | 0.81 | ASCEND-4 (Soria et al. [5]) |
 Treatment response: Ceritinib | 0.81 | |
 Stable disease: crizotinib | 0.81 | |
 Treatment response: Crizotinib | 0.81 | |
 Disease progression: all treatments | 0.64 | Chouaid et al. [27] |
Hazard ratios | ||
 PFS: Ceritinib vs. Crizotinib | 0.64 (0.47, 0.87) | Li et al. [17] |
 OS: Ceritinib vs. Crizotinib | 0.82 (0.54, 1.27) | |
Unit cost | ||
 Ceritinib (450 mg) | $52.77 per pill | Hong Kong Hospital Authority [1] |
 Crizotinib (250 mg) | $113.21 per pill | |
Relative dose intensity | ||
 Ceritinib | 92.2% | ASCEND-8 [6] |
 Crizotinib | 92.0% | PROFILE 1014 (Australian Department of Health) [15] |
Monthly medical costs/ pre-progression frequency/post-progression frequency | ||
 Cancer nurse | $12.82/ 0.1 time per month/0.1 time per month | Hong Kong Hospital Authoritya |
 Outpatient visit | $142.31/ 1 time per month / 1.08 times per month | |
 Pharmacist | $49.36/ 1 time per month /0.1 time per month | |
 Complete blood count | $17.31 / 1 time per month / 1.08 times per month | |
 CT scan | $1,730.77/ 0.25 time per month / 0.18 time per month | |
 MRI | $602.56/ 0.17 time per month /0.12 time per month | |
 X-Ray | $24.36/ 1 time per month / 1.08 times per month | |
 Serum chemistry | $116.03/ 1 time per month / 1.08 times per month | |
Total post-progression treatment costs | ||
 Ceritinib | $11,142.92 | ASCEND-4; PROFILE 1014 [15]; Hong Kong Hospital Authority [1] and literature |
 Crizotinib | $10,385.68 | |
 Terminal care cost | $24,089.00 | Wong et al. [25] |
Costs associated with AEs | ||
 Ceritinib | $2,024.93 | ASCEND-8 (Cho et al. [6] PROFILE 1014 (Solomon et al. [15]) Hong Kong Hospital Authority [1] |
 Crizotinib | $1,236.39 | |